Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in mRCC with Brain Metastases
NCT03967522Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Nov 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in metastatic renal cell carcinoma (mRCC), sponsored by Centre Léon Bérard. Started Nov 2019; status: completed.
02
Drugs
cabozantinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03967522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03967522.